Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.170
-0.002 (-0.99%)
Mar 5, 2026, 2:40 PM EST - Market open
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$33,500,093
Market Cap
2.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Artelo Biosciences | 5 |
| Adial Pharmaceuticals | 5 |
| XORTX Therapeutics | 3 |
PPCB News
- 2 days ago - Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models - GlobeNewsWire
- 15 days ago - Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - GlobeNewsWire
- 4 weeks ago - Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - GlobeNewsWire
- 5 weeks ago - Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - GlobeNewsWire
- 6 weeks ago - Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - GlobeNewsWire
- 7 weeks ago - Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Propanc Biopharma Provides Shareholder Update - GlobeNewsWire
- 2 months ago - Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - GlobeNewsWire